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Abstract
GWAS of prostate cancer have been remarkably successful in revealing common genetic variants and novel biological
pathways that are linked with its etiology. A more complete understanding of inherited susceptibility to prostate cancer in
the general population will come from continuing such discovery efforts and from testing known risk alleles in diverse racial
and ethnic groups. In this large study of prostate cancer in African American men (3,425 prostate cancer cases and 3,290
controls), we tested 49 risk variants located in 28 genomic regions identified through GWAS in men of European and Asian
descent, and we replicated associations (at p#0.05) with roughly half of these markers. Through fine-mapping, we identified
nearby markers in many regions that better define associations in African Americans. At 8q24, we found 9 variants
(p#661024) that best capture risk of prostate cancer in African Americans, many of which are more common in men of
African than European descent. The markers found to be associated with risk at each locus improved risk modeling in
African Americans (per allele OR= 1.17) over the alleles reported in the original GWAS (OR= 1.08). In summary, in this
detailed analysis of the prostate cancer risk loci reported from GWAS, we have validated and improved upon markers of risk
in some regions that better define the association with prostate cancer in African Americans. Our findings with variants at
8q24 also reinforce the importance of this region as a major risk locus for prostate cancer in men of African ancestry.
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Introduction
Genome-wide association studies (GWAS) have revealed more
than 30 variants that contribute susceptibility to prostate cancer,
with most of the discoveries having been made in populations of
European ancestry [1–14]. However, as so far observed for most
common diseases, variants identified through GWAS are of low
risk both individually and in aggregate, and therefore provide only
limited information about disease prediction [15,16]. Most risk
variants for prostate cancer are located outside of annotated genes,
with some positioned in gene poor regions and some regions
harboring more than one independent signal [1,10,14,17,18].
Thus, for the vast majority of risk loci, the identity, frequency and
risk associated with the underlying biologically relevant allele(s) are
unknown. The risk variants revealed through GWAS have also
been found to vary in frequency across racial/ethnic populations
[19]. Even in the absence of functional data, the associated risk
variants may highlight a genetic basis for differences in disease risk
between populations, such as at 8q24 where genetic variation is
suggested to contribute to population differences in risk of prostate
cancer [10]. Testing of the risk variants and fine-mapping in
diverse populations will help to identify and localize the subset of
markers that best define risk of the functional allele(s) within
known risk loci, as well as to determine their contribution to racial
and ethnic differences in prostate cancer risk.
In the present study, we tested common genetic variation at the
prostate cancer risk loci identified in men of European and Asian
descent in a large sample comprised of 3,425 African American
prostate cancer cases and 3,290 controls, to identify markers of risk
that are relevant to this population. More specifically, we
conducted GWAS and imputation-based fine-mapping of each
risk locus to both improve the current set of risk markers in African
Americans as well as to identify new risk variants for prostate
cancer. We then applied this information to model the genetic risk
of prostate cancer in African American men.
Results
The African American prostate cancer cases (n = 3,621) and
controls (n = 3,502) in this study are part of a collaborative
genome-wide scan of prostate cancer that includes 11 individual
studies (Table S1, Methods). Samples were genotyped using the
Illumina Infinium 1M-Duo bead array, and following quality
control exclusions (see Methods), the analysis of variants at the
known risk loci was performed on 3,425 cases and 3,290 controls.
The ages of cases and controls ranged from 23 to 95, with cases
and controls having similar ages (mean 65 and 64 years,
respectively).
We tested 49 known prostate cancer risk variants located in 28
risk regions (Table S2, Table 1, and Table 2); 43 SNPs were
directly genotyped (with call rates .95%), while 6 were imputed
with high accuracy (see Methods) [1,3,4,6–14,17,18,20–23]. The
minor allele frequencies (MAF) of all 49 variants were common
($0.05) in African Americans, except for rs721048 at 2p15 (MAF,
0.04) and rs12621278 at 2q21 (MAF, 0.02; Table 1, Figure 1). On
average, across all variants tested, the risk allele frequencies (RAFs,
i.e. alleles associated with an increased risk of prostate cancer in
previous GWAS) were 0.05 greater in African Americans than in
Europeans. However, when removing the 12 risk variants at 8q24
(Table 2) the average difference in RAF over the remaining risk
loci was only 0.03.
We examined the association of local ancestry with prostate
cancer risk at each of the 28 risk regions (Table S3). In addition to
8q24, which we had previously found to be strongly associated
with African ancestry [5] (OR per European chromosome=0.81,
p = 4.761025), we observed significant associations at 22q13
(OR=0.88, p = 0.01), 7p15 (OR=1.16, p = 1.661023) and 10q26
(OR=1.14, p = 6.261023). To address the potential for con-
founding by genetic ancestry, we adjusted for both global and local
ancestry in all analyses (see Methods).
In previous GWAS, the index signals outside of 8q24 had very
modest odds ratios (1.05–1.30 per copy of the risk allele) and our
sample size provided $80% power to detect the reported effects
for 24 of the 37 variants (at p,0.05; Table S2). We observed
positive associations with 28 of the 37 variants (odds ratios (OR)
.1) in African Americans and 18 reached nominal statistical
significance (p#0.05; Table 1). Results were similar without
adjustment for local ancestry in each region (Table S4). Of the 19
variants that were not replicated at p,0.05, power was ,80% for
9 of the variants.
While power was limited to detect associations at some loci, the
lack of replication at loci where power was acceptable (.80%)
suggests that the particular risk variant revealed in GWAS in
European and Asian populations may not be adequately correlated
with the biologically relevant allele in African Americans. In an
attempt to identify a better genetic marker of the biologically
relevant allele in African Americans we conducted fine-mapping
across all risk regions using genotyped SNPs on the 1 M array and
imputed SNPs to Phase 2 HapMap (Table S5, see Methods). If a
marker associated with risk in African Americans represents the
same signal as that reported in the initial GWAS, then it should be
correlated to some degree with the index signal in the initial GWAS
population. Using HapMap data (CEU or JPT+CHB depending
upon the initial GWAS population) we catalogued and tested all
SNPs that were correlated (r2$0.2) with the index signal (within
250 kb), applying a significance criteria aa, of 0.004 given the large
number of correlated tests. This level of significance was based on
the number tag SNPs in the HapMap YRI population that capture
(r2$0.8) all SNPs that were correlated with the index signal in the
HapMap CEU (r2$0.2; see Methods). We also looked for novel
independent associations, focusing on the genotyped and imputed
SNPs that were uncorrelated with the index signal in the initial
GWAS populations. Here, we applied a Bonferroni correction for
defining novel associations as significant in each region, with ab
estimated as 0.05/the total number of tags needed to capture
(r2$0.8) all common risk alleles across all risk region in the YRI
population (ab = 5.6610
26). This is similar to the genome-wide-
type correction of 561028, which accounts for the number of tags
Author Summary
Prostate cancer is one of the most common cancers in
men and is especially frequent in men of African origin, as
incidence rates in African Americans in the United States
are .1.5–fold greater than rates in European Americans. In
order to gain a more complete understanding of the
genetic basis of inherited susceptibility to prostate cancer
in men of African origin, we examined the associations at
risk loci identified in men of European and Asian descent in
a large African American sample of 3,425 cases of prostate
cancer and 3,290 male controls. In testing 49 known risk
variants, we were able to demonstrate that at least half of
these variants also contribute to risk in African American
men. We were able to find additional risk variants in many
of the previously reported regions that better captured the
pattern of risk in African American men. In addition, we
verified and improved upon the evidence we previously
reported that there are multiple risk variants in a region of
8q24 that are important in men of African origin.
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Table 1. Associations with common variants at known prostate cancer risk regions in African Americans (3,425 cases, 3,290 controls).
Index SNP from GWAS Best Marker in African Americans
Chr., Marker
Position, Allelesa
RAF (EA/AA)b, OR (95% CI)c
P-valued
Marker, Position,
Allelesa
RAF (AA)b, OR (95% CI)c
P-value
r2 with index in GWAS
population/YRIe
2p24,rs13385191 20,751,746,G/A 0.61f/0.06, 0.99(0.84–1.16) 0.90 rs340623g 20,795,759,C/T 0.17, 1.15(1.05–1.27) 3.861023 0.44k/0h
2p21,rs1465618 43,407,453,T/C 0.23/0.12, 1.07(0.96–1.20) 0.22 -----j
2p15, rs721048 62,985,235,A/G 0.19/0.04, 1.24(1.03–1.50) 0.025 -----
2p15,rs2710647 63,067,474,C/T 0.55/0.46, 1.16(1.08–1.25) 2.861025 rs6545977 63,154,668,G/A 0.48, 1.18(1.10–1.27) 2.361026 0.42/0.44
2q21,rs12621278 173,019,799,A/G 0.94/0.98, 1.44(1.05–1.99) 0.026 rs12620581g 173,037,960,A/G 0.75, 1.13(1.04–1.23) 3.861023 0.29/0h
3p12,rs2660753 87,193,364,T/C 0.11/0.49, 0.97(0.90–1.05) 0.50 -----
3q21,rs10934853 129,521,063,A/C 0.28/0.70, 1.03(0.95–1.13) 0.43 rs7641133 129,319,009,T/C 0.29, 1.16(1.08–1.25) 1.061024 0.91/0.11
4q22,rs12500426 95,733,632,A/C 0.46/0.40, 1.00(0.93–1.07) 0.99 -----
4q22,rs17021918 95,781,900,C/T 0.66/0.78, 1.08(0.99–1.18) 0.066 -----
4q24,rs7679673g 106,280,983,C/A 0.55/0.39, 1.08(1.00–1.16) 0.050 -----
5p15,rs401681 1,375,087,C/T 0.55/0.41, 0.94(0.87–1.00) 0.068 -----
5p15,rs12653946 1,948,829,T/C 0.43f/0.41, 1.05(0.98–1.13) 0.15 -----
6p21,rs1983891 41,644,405,T/C 0.38f/0.48, 1.09(1.01–1.17) 0.024 -----
6q22,rs339331 117,316,745,T/C 0.63f/0.75, 1.22(1.12–1.32) 3.161026 rs12202378g 117,348,714,T/C 0.70, 1.25(1.15–1.35) 8.861028 1.0k/0.79
6q25,rs9364554 160,753,654,T/C 0.29/0.06, 1.30(1.11–1.52) 8.261024 rs2076828 160,792,776,C/G 0.56, 1.14(1.06–1.22) 3.561024 0.29/0h
7p15,rs10486567 27,943,088,G/A 0.77/0.71, 1.15(1.07–1.25) 2.961024 rs7808935g 27,943,888,T/C 0.70, 1.16(1.07–1.25) 2.661024 0.93/1.0
7q21,rs6465657 97,654,263,C/T 0.46/0.87, 1.00(0.87–1.14) 0.95 -----
8p21,rs2928679 23,494,920,A/G 0.42/0.27, 1.02(0.94–1.10) 0.60 -----
8p21,rs1512268 23,582,408,T/C 0.45/0.63, 1.12(1.04–1.20) 3.261023 rs11782388g 23,581,303,C/T 0.70, 1.18(1.09–1.28) 9.861025 0.95/0.63
10q11,rs10993994 51,219,502,T/C 0.40/0.60, 1.09(1.02–1.17) 0.017 rs4630243g 51,210,873,T/C 0.76, 1.14(1.05–1.25) 2.361023 0.74/0.27
10q26, rs4962416 126,686,862,C/T 0.27/0.16, 1.05(0.96–1.16) 0.28 -----
11p15, rs7127900 2,190,150,A/G 0.20/0.36, 1.09(1.01–1.17) 0.027 -----
11q13,rs12418451g 68,691,995,A/G 0.28/0.13, 1.13(1.01–1.27) 0.030 -----
11q13,rs11228565 68,735,156,A/G 0.20/0.10, 1.08(0.96–1.21) 0.18 rs11228580g 68,758,918,C/T 0.16, 1.31(1.20–1.44) 9.761029 0.53/0.05
11q13, rs7931342 68,751,073,G/T 0.51/0.78, 1.13(1.03–1.24) 8.961023 -----
11q13,rs10896449 68,751,243,G/A 0.52/0.67, 1.15(1.06–1.24) 3.761024 -----
13q22,rs9600079 72,626,140,T/G 0.35f/0.52, 0.98(0.91–1.05) 0.53 -----
17p12, rs4054823 13,565,749,T/C 0.56/0.68, 0.99(0.92–1.06) 0.74 -----
17q12,rs11649743 33,149,092,G/A 0.80/0.91, 1.15(1.01–1.31) 0.041 -----
17q12, rs4430796 33,172,153,A/G 0.53/0.35, 1.02(0.95–1.10) 0.52 -----
17q12,rs7501939 33,175,269,C/T 0.58/0.49, 1.03(0.96–1.10) 0.44 -----
17q24, rs1859962 66,620,348,G/T 0.46/0.30, 0.99(0.92–1.07) 0.84 -----
19q13, rs8102476 43,427,453,C/T 0.54/0.74, 1.12(1.03–1.21) 8.561023 -----
19q13, rs266849 56,040,902,A/G 0.80/0.88, 1.01(0.91–1.13) 0.85 rs3760722i 56,049,628,C/T 0.72, 1.14(1.05–1.24) 1.561023 0.22/0.02
19q13, rs2735839 56,056,435,G/A 0.85/0.69, 0.94(0.87–1.02) 0.12 -----
22q13, rs5759167 41,830,156,G/T 0.53/0.75, 1.10(1.01–1.20) 0.024 -----
Xp11, rs5945572 51,246,423,A/G 0.35/0.14, 1.21(1.09–1.35) 5.261024 rs4907796 51,277,989,T/C 0.13, 1.25(1.12–1.39) 7.161025 0.87/0.72
aRisk allele/reference allele.
bRAF, risk allele frequency in populations of European ancestry (EA) or HapMap CEU population, and in African Americans (AA) in this study. This is the allele associated
with increased risk in previous GWAS.
cAdjusted for age, study, the 1st 10 eigenvalues and local ancestry at each risk locus.
dTest of trend (1-d.f.).
ePairwise correlation between the index signal and the best marker in African Americans in CEU or JPT (where indicated) in 1000 Genomes Project (March 2010 release).
fIndex signal reported in Japanese. RAFs and r2 based on Japanese data [11] or JPT in 1000 Genomes.
gImputed (Rsq$0.87).
hBest marker or index marker in AA is extremely rare or monomorphic in YRI.
ir2 of rs3760722 and rs2735839 in YRI is 0.24.
jNo SNP selected in stepwise procedure.
kEstimated in HapMap JPT/CHB.
doi:10.1371/journal.pgen.1001387.t001
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Table 2. Associations with risk variants at 8q24 in African Americans.
African Americans (3,425 cases, 3,290 controls)
Regiona, Position Marker, Allelesb RAFc (EA/AA) OR (95% CI)d P-valuee
OR (95% CI)
Adjustedf P-value R2 g
1, 127,993,841 rs12543663, C/A 0.31/0.15 0.89(0.80–0.99) 0.028 0.91(0.82–1.02) 0.10 0.07
1, 128,081,119 rs10086908, T/C 0.70/0.75 1.13(1.04–1.22) 4.561023 1.13(1.04–1.23) 4.261023 0.06
2, 128,162,479 rs1016343, T/C 0.20/0.22 1.03(0.95–1.12) 0.51 1.02(0.94–1.11) 0.68 0.03
2, 128,164,338 rs13252298, A/G 0.70/0.93 1.09(0.93–1.27) 0.28 1.04(0.89–1.22) 0.60 0.12
2, 128,173,525 rs13254738h, C/A 0.35/0.60 1.25(1.16–1.36) 2.161028 1.17(1.07–1.28) 7.361024 0.31
2, 128,176,062 rs6983561h, C/A 0.04/0.44 1.29(1.19–1.39) 5.6610210 1.20(1.09–1.31) 1.061024 0.33
3, 128,404,855 rs620861, G/A 0.61/0.65 1.06(0.99–1.14) 0.11 1.07(0.99–1.15) 0.088 0.06
3, 128,410,090 rs16902104, T/C 0.14/0.07 1.01(0.88–1.16) 0.88 0.97(0.84–1.12) 0.72 0.05
4, 128,482,487 rs6983267, G/T 0.51/0.88 1.24(1.09–1.42) 1.561023 1.20(1.04–1.38) 0.011 0.21
4, 128,510,352 rs7000448h, T/C 0.36/0.62 1.11(1.02–1.20) 0.012 1.08(0.99–1.18) 0.070 0.16
5, 128,600,871 rs11986220h, A/T 0.09/0.05 1.39(1.20–1.61) 1.561025 1.28(1.06–1.56) 0.011 0.42
5, 128,601,319 rs10090154h, T/C 0.09/0.13 1.22(1.10–1.35) 2.061024 1.08(0.95–1.24) 0.24 0.42
Stepwise Analysisi
Regiona, Position Marker, Allelesb RAFc (EA/AA) OR (95% CI)d P-valuee
OR (95% CI)
Adjustedf P-value R2 g
1,127,994,810 rs7839365h, T/A 0.60/0.61 1.18(1.09–1.27) 1.761025 1.16(1.08–1.26) 1.161024 0.01
1,128,059,437 rs753228h, C/T 0.96/0.95 1.41(1.18–1.68) 1.561024 1.43(1.20–1.72) 9.961025 0.02
2,128,162,723 rs4871008h, C/T 0.57/0.67 1.19(1.10–1.28) 7.461026 1.15(1.06–1.24) 7.961024 0.10
2,128,173,119 rs1456315, T/C 0.28/0.53 1.23(1.15–1.33) 8.061029 1.27(1.18–1.37) 4.2610210 0.06
2,128,200,973 rs10098156h, G/C 0.90/0.88 1.26(1.11–1.44) 4.961024 1.30(1.13–1.49) 2.261024 0.09
2,128,219,343 rs6987409h, T/C 0.0/0.15 1.42(1.28–1.57) 1.8610211 1.33(1.20–1.48) 1.161027 0.08
4,128,528,307 rs13282506h, G/A 0.73/0.88 1.25(1.09–1.43) 1.361023 1.28(1.12–1.47) 3.861024 0.006
5,128,589,355 rs7812429h, A/G 0.06/0.08 1.31(1.15–1.48) 3.461025 1.30(1.15–1.48) 5.061025 0.002
5,128,640,941 rs4313118, T/C 0.77/0.79 1.16(1.07–1.27) 6.261024 1.17(1.07–1.28) 4.161024 0.001
aRisk regions as defined in [1,2,7,10,13].
bRisk /reference alleles.
cRAF, risk allele frequency in populations of European ancestry [1,6 or HapMap CEU] and in African Americans (AA).
dAdjusted for age, study, the 1st 10 eigenvalues and local ancestry for region 127.8–129.0 Mb (NCBI build 36).
eTest of trend (1-d.f.).
fFrom the multivariate model. OR adjusted for age, study, the 1st 10 eigenvalues, local ancestry and all other 8q24 risk variants.
gThe proportion of the variance explained by the other SNPs.
hImputed (Rsq$0.76). rs445114 was not genotyped and could not be imputed [6].
iSNPs kept in stepwise procedure if p,0.001.
doi:10.1371/journal.pgen.1001387.t002
Figure 1. Risk Allele Frequencies in Europeans and African Americans. The distribution of risk allele frequencies (RAF) for the 49 index SNPs
(from Table 1 and Table 2) in Europeans (EA) and African Americans (AA). The variants are sorted based on the RAF in EAs.
doi:10.1371/journal.pgen.1001387.g001
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needed to capture all common alleles in the genome. For each
region, stepwise regression was used with SNPs kept in the final
model based on aa or ab (results for each model are provided in
Table S6).
Among the SNPs correlated with the index signal in the GWAS
population, a more significantly associated marker was identified
at 12 regions. For 5 of these regions, the new marker showed only
a slightly more significant association than the index signal (,1
order of magnitude change in the p-value; Table 1). However, for
7 regions (2p24, 2p15, 3q21, 6q22, 8q21, 11q13, and 19q13), the
new marker appeared to capture risk more strongly than the index
signal in African Americans. The risk region at 3q21 is provided in
Figure 2 as an example. Here the index signal was not significantly
associated with risk in African Americans (rs10934853, OR=1.03,
95% CI, 0.95–1.03, p = 0.43), with the most significantly
associated marker in African Americans located ,200 kb
centromeric from the index signal (rs7641133, OR=1.16, 95%
CI 1.08–1.25, p = 1.061024). These two markers are strongly
correlated in Europeans (HapMap CEU, r2 = 0.91) but not in
Africans (HapMap YRI, r2 = 0.11; Table 1), which suggests that in
African Americans rs7641133 is a better proxy of the biologically
important allele and may better localize the true association. For
some of these regions, the size of the LD blocks differ in
populations of African ancestry compared with the GWAS
population and thus, may assist in localizing the functional allele
(Figure S1). Using a strict ab of 5.6610
26 for discovery of novel
risk variants we observed no evidence of a second independent
signal at any risk region. For variants identified as significantly
associated with risk (Table 1), odds ratios for homozygous carriers
were generally greater than for heterozygous carriers, which
provides support for their associations (Table S7).
We examined 12 risk variants at 8q24 that had been reported
previously to be associated with prostate cancer risk
[1,7,10,13,14,20] with 7 being statistically significant and posi-
tively associated with risk (p,0.05). The risk SNP BD11934905
[10] is not on the Illumina 1 M array and was not genotyped in
this study. In contrast with what has been reported in Europeans,
the risk allele for rs12543663 was observed to be significantly
inversely associated with risk in African Americans (OR=0.89,
p = 0.028; Table 2). The RAFs for 8 of the 12 alleles are more
common in African Americans than Europeans, with the average
RAF being 0.46 in African Americans and 0.32 in Europeans. The
largest difference in RAFs between populations are noted with
variants rs13252298, rs13254738, rs6983561, rs6983267 and
rs7000448, which have RAFs that are .0.20 greater in African
Americans than in Europeans. When all 12 variants were included
in a multivariate model, only 5 remained nominally associated
with risk (Table 2). In African Americans, many of these index
signals were weakly correlated (Figure S2) and demonstrated
stronger multi-allelic correlations (Table 2), which suggests that
some variants may define similar haplotypes marking the same
biologically relevant variants in this population. No significant
association was observed with rs7008482 (OR=0.96, p = 0.52,
computed using data included in the initial report [24]) or markers
of risk at 8q24 for cancers of the breast, bladder, ovary, or
leukemia (rs13281615: OR=1.03, p = 0.48; rs9642880: OR=
1.07, p = 0.13; rs10088218: OR=0.91, p = 0.06; rs2456449:
OR=1.06, p= 0.24) [25–28].
To identify markers at 8q24 that best capture risk in African
Americans we performed a stepwise analysis of 1,549 genotyped
and imputed SNPs spanning the established risk locus (127.8–
129.0 Mb). This region contained 132 SNPs with nominal p-
values,0.001 (Figure 3), and 9 common alleles with per allele
ORs of 1.16–1.42 (Table 2) defined the most parsimonious model.
Similarly to the previously reported risk variants at 8q24 four of
these markers are substantially more common in African
Americans than Europeans (average RAF difference = 0.07). Eight
of these markers show some degree of correlation with the known
risk variants and thus are likely to be tagging the same functional
allele, albeit for 4 SNPs the correlations are quite weak in the CEU
Figure 2. 2Log P Plot for Common Alleles at the Chromosome
3q21 Prostate Cancer Risk Locus. The index signal (rs10934853) is
designated by a purple diamond. The r2 shown is that in Europeans
from HapMap (CEU) in relation to rs10934853. 2Log P-values are those
observed in African Americans from logistic regression models adjusted
for age, study, global ancestry (the 1st 10 eigenvectors) and local
ancestry. Circles are genotyped SNPs and squares are imputed SNPs.
Grey circles are SNPs not in HapMap (r2 can not be estimated). The plot
was generate using LocusZoom [45].
doi:10.1371/journal.pgen.1001387.g002
Figure 3. 2Log P Plot for Common Alleles at 8q24 in African
Americans. 2Log P-values for alleles in the region 127.8–129.0 Mb in
African Americans from logistic regression models adjusted for age,
study, global ancestry (the 1st 10 eigenvectors) and local ancestry.
Pairwise correlations in the HapMap YRI population are shown in
relation to rs6987404, which was the most significant marker in the
region (p = 1.8610211). Circles are genotyped SNPs and squares are
imputed SNPs. Grey circles are SNPs not in HapMap (r2 can not be
estimated). The lines below demarcate the five risk regions (R) as
defined in [1,2,7,10,13]. The plot was generate using LocusZoom [45].
The nine SNPs highlighted are from the stepwise analysis presented in
Table 2.
doi:10.1371/journal.pgen.1001387.g003
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and YRI populations (r2,0.2; Table S8) suggesting that they may
be marking independent risk variants. For example, SNP
rs6987409 (RAF=0.15), which is monomorphic in Europeans,
remains significantly associated with risk conditional on the 12
known risk alleles at 8q24 (OR=1.31, 95% CI, 1.16–1.47,
p = 7.161026), which suggests that this SNP may be marking a
novel variant that is relevant in African Americans; rs6987409 was
the most significant marker in the region (Figure 3).
We next estimated the cumulative effect of all prostate cancer risk
alleles, and compared a summary risk score comprised of
unweighted counts of all GWAS reported risk alleles to a risk score
that included variants we identified as being associated with risk in
African Americans (Table 3). Using index signals from GWAS (see
Methods), the risk per allele was 1.08 (95% CI, 1.06–1.09;
p= 6.0610226) and individuals in the top quartile of the risk allele
distribution were at 2-fold greater risk of prostate cancer compared
to those in the lowest quartile (Table 3). As expected, the risk score
was improved when utilizing the markers that we identified at the
known risk loci as being more relevant to African Americans
(OR=1.17 95% CI, 1.15–1.19; p= 5.1610274), with risk for those
in the top quartile being 3.5-times those in the lowest quartile. When
stratifying by first-degree family history of prostate cancer, risk was
4.7-fold greater for those with a family history and in the top quartile
of the risk score distribution (3.5% of the population) compared to
those without a family history and in the first quartile (Table 3). The
risk score was associated equally with risk for advanced (n= 1,087)
and non-advanced (n= 1,968) prostate cancer (case-only test:
OR=1.02, 95% CI, 1.00–1.05 phet = 0.082).
Using this risk score, we estimate (see Methods) that in the
aggregate, all risk alleles tested explain approximately 11% of risk
in first-degree relatives of cases.
Discussion
In this large study of prostate cancer risk in African American
men we tested 49 variants that had been reported primarily in
populations of European and Asian ancestry, and we were able to
replicate associations (at p#0.05) with roughly half of these
markers. We had adequate power (.80%) to detect relative risks
of the magnitude reported previously for the majority of risk
variants (although we realize that power was overestimated as the
effect estimates from the initial report may be inflated due to the
winner’s curse phenomenon [29].) Through fine-mapping, we
identified markers in many regions that were more strongly
associated with risk in African Americans than the index variant,
and thus, are likely to be better proxies of the biologically relevant
allele in this population. Our ability to detect associations in
African Americans with either the index signal or correlated
variants suggests that most loci contain a biologically relevant
allele that is not unique to the initial GWAS population. These
findings improve upon previous studies to replicate associations in
African Americans [30], efforts which included some of these same
studies, but in substantially smaller sample sizes for most variants
examined [19,31].
Within 12 regions, fine-mapping in African Americans revealed
a more significantly associated marker (with evidence over the
index signal being clearly greater at 7 loci). For some of the
regions, the signal in African Americans was located in a smaller
region of LD than that observed in the GWAS population which
should aid in localizing the functional variant(s). Confirmation of
these associations in the initial GWAS populations will be required
before they can be declared as proxies of the underlying functional
alleles; however in many cases, given their modest to strong
Table 3. The association of the total risk score with prostate cancer risk in African Americans.
Index Markers from
GWAS (n=40) Risk-associated Markers in African Americans (n=27)
Mean number of risk alleles in controls,
(range)
41(24–54) 31(20–43)
OR per allele (95% CI)a 1.08(1.06–1.09) 1.17(1.15–1.19)
P-value 6.0610226 5.1610274
All cases/controls
(3425/3290)
First-Degree Family History
Negativec
(2505/2454)
First-Degree Family History
Positivec
(574/317)
Quartiles of Risk Allelesb
Q1 n (cases/controls) 603/824 441/834 328/610 66/92
OR(95% CI) 1.0(ref.) 1.0(ref.) 1.0(ref.) 1.19(0.83–1.72)
P-value - - - 0.34
Q2 n (cases/controls) 775/915 717/853 530/615 122/69
OR(95% CI) 1.16(1.00–1.34) 1.60(1.37–1.87) 1.50(1.25–2.18) 3.00(2.14–4.22)
P-value 0.05 4.661029 1.861025 2.1610210
Q3 n (cases/controls) 841/732 804/795 601/598 128/69
OR(95% CI) 1.55(1.33–1.80) 1.89(1.62–2.21) 1.81(1.51–2.18) 2.94(2.10–4.12)
P-value 1.061028 1.1610215 2.8610210 3.8610210
Q4 n (cases/controls) 1206/823 1463/808 1046/591 258/87
OR(95% CI) 2.02(1.75–2.33) 3.51(3.02–4.07) 3.33(2.79–3.97) 4.66(3.48–6.23)
P-value 9.4610222 6.9610261 1.6610240 3.4610225
aOdds ratios (and 95% confidence intervals) adjusted for age, study, and the 1st 10 eigenvalues.
bQuartiles based on distribution in controls (cutpoints for 40 SNPs: 37.5, 40.0 and 42.7; 27 SNPs: 28.7, 30.9 and 32.8).
cInformation about family history of prostate cancer is available on 90% of cases and 84% of controls.
doi:10.1371/journal.pgen.1001387.t003
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correlation, based on HapMap data, with the index signal in the
GWAS population, most markers are expected to be strongly
associated with risk. At each locus, fine-mapping was based on the
Illumina 1 M-Duo content supplemented with SNPs imputed
from Phase 2 HapMap (CEU/YRI), which is expected to provide
good coverage of the vast majority of common alleles in the
admixed African American population. Of the ,1.5 million
common SNPs (MAF$0.05) in the HapMap YRI population that
we did not genotype, we were able to impute ,1.4 million with
Rsq$0.8. Our inability to detect associations at 10 regions
(p.0.05 for an index signal and p.0.004 for a proxy) could be
due to low power, the functional allele being rare or non-existent
in African Americans and/or inadequate tagging in these specific
regions.
Because of limited LD, fine-mapping in African Americans is
thought to be an effective approach for localizing functional risk
alleles for common phenotypes as populations of African ancestry
are expected to have, on average, fewer alleles that are correlated
with a functional variant. Fine-mapping in multiple racial/ethnic
populations should prove to be even more powerful for isolating
these variants as only a subset SNPs that are correlated with the
functional allele in different populations will be similar. Thus,
conducting association testing across multiple populations should
narrow the subset of potentially functional alleles in a region. A
complete resource of genome-wide variation data from multiple
populations provided by the 1000 Genomes Project will assist in
further interrogating these risk loci and together with large-scale
association testing in diverse samples, will guide researchers in
defining the subset of alleles that are correlated with risk across
populations and hence are the most logical candidates for
functional characterization.
A number of prostate cancer risk regions have been found to
harbor more than one risk variant (e.g. 8q24, 17q12 and 11q13)
[1,10,17,18]. Aside from 8q24, the search for independent
markers at known risk loci has been limited to populations of
European ancestry. Using a relatively strict threshold for declaring
significance (average a,5.661026), we observed no evidence of
association that is independent of the index signal. While
suggestive associations were observed at many loci, testing of
these variants in additional African American samples will be
needed to confirm these associations, followed by testing in other
populations to assess whether the associations may be limited to
African Americans.
The risk region at 8q24 is the strongest susceptibility locus for
prostate cancer that has been identified to date, with a number of
different risk variants having been reported in different popula-
tions [1,6,7,10,13,14]. We identified nine SNPs at 8q24 that best
captured the genetic risk in African Americans, including SNP
rs6987409 [1] which is not observed in Europeans (or is present at
an extremely low frequency). Like the reported index signals at
8q24 (Table 2), many of these markers are more common in
African Americans than in Europeans (average RAF differ-
ence = 0.07). This is in contrast to the index signals in regions
outside of 8q24 where the RAF average difference was only 0.03.
If the frequency of these 8q24 variants is a good correlate of the
frequency of the underlying biologically relevant alleles then some
of the variants in this region may to contribute to the excess risk of
prostate cancer in African Americans, as suggested previously
[10]. A precise estimate of its contribution will only come once the
functional alleles have been found and we understand their
associations in the context of other genetic and environmental
factors (or host factors such as age).
The cumulative effects of GWAS-identified variants for
common cancers are not yet clinically informative for risk
prediction [15,16]. Until the functional alleles are identified and
their effects are accurately estimated, modeling of the genetic risk
will rely on markers that best capture risk at an established
susceptibility locus for a given population. Many of the markers we
identified at these risk loci in African Americans appear to provide
substantial improvement over the GWAS-identified variants in
defining those who are at greater risk of prostate cancer in this
population. However, as estimated with the index signals in
European populations [3], these alleles likely account for only a
small fraction of the familial risk of the disease (,10%) in African
Americans. Validation of this risk model in African Americans and
in other populations will be needed, as will incorporating novel risk
variants identified through this GWAS in African American men.
Methods
Ethics Statement
The Institutional Review Board at the University of Southern
California approved the study protocol.
Study Populations
Nine studies were genotyped as part of the GWAS of prostate
cancer in African American men. Below is a brief description of
each study.
The Multiethnic Cohort (MEC). The MEC includes
215,251 men and women aged 45–75 years at recruitment from
Hawaii and California [32]. The cohort was assembled in 1993–
1996 by mailing a self-administered, 26-page questionnaire to
persons identified primarily through the driver’s license files.
Identification of incident cancer cases is by regular linkage with the
Hawaii Tumor Registry and the Los Angeles County Cancer
Surveillance Program; both NCI-funded Surveillance, Epide-
miology, and End Results registries. From the cancer registries,
information is obtained about stage and grade. Collection of
biospecimens from incident prostate cases began in California in
1995 and in Hawaii in 1997 and a biorepository was established
between 2001 and 2006 from 67,000 MEC participants. The
participation rates for providing a blood sample have been greater
than 60%. Through January 1, 2008 the African American case-
control study in the MEC included 1,094 cases and 1,096 controls.
The Southern Community Cohort Study (SCCS). The
SCCS is a prospective cohort of African and non-African
Americans which during 2002–2009 enrolled approximately
86,000 residents aged 40–79 years across 12 southern states
[33]. Recruitment occurred mainly at community health centers,
institutions providing basic health services primarily to the
medically uninsured, so that the cohort includes many adults of
lower income and educational status. Each study participant
completed a detailed baseline questionnaire, and nearly 90%
provided a biologic specimen (approximately 45% a blood sample
and 45% buccal cells). Follow-up of the cohort is conducted by
linkage to national mortality registers and to state cancer registries.
Included in this study are 212 incident African American prostate
cancer cases and a matched stratified random sample of 419
African American male cohort members without prostate cancer
at the index date selected by incidence density sampling.
The Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO). The Prostate, Lung, Colorectal,
and Ovarian Cancer Screening Trial [34], is a randomized,
two-arm trial among men and women aged 55–74 years to
determine if screening reduced the mortality from these cancers.
Male participants randomized to the intervention arm underwent
prostate specific antigen (PSA) screening at baseline and annually
for 5 years and digital rectal examination at baseline and annually
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for 3 years. Sequential blood samples were collected from
participants assigned to the screening arm; participation was
93% at the baseline blood draw (1993–2001). Buccal cell samples
were collected from participants in the control arm of the trial;
participation was about 85% for this component. Included in this
study are 286 African American prostate cancer cases and 269
controls without a history of prostate cancer, matched on age at
randomization and study year of the trial.
The Cancer Prevention Study II Nutrition Cohort (CPS-
II). The CPS-II Nutrition Cohort includes over 86,000 men and
97,000 women from 21 US states who completed a mailed
questionnaire in 1992 (aged 40–92 years at baseline) [35]. Starting
in 1997, follow-up questionnaires were sent to surviving cohort
members every other year to update exposure information and to
ascertain occurrence of new cases of cancer; a.90% response rate
has been achieved for each follow-up questionnaire. From 1998–
2001, blood samples were collected in a subgroup of 39,376 cohort
members. To further supplement the DNA resources, during
2000–2001, buccal cell samples were collected by mail from an
additional 70,000 cohort members. Incident cancers are verified
through medical records, or through state cancer registries or
death certificates when the medical record can not be obtained.
Genomic DNA from 76 African American prostate cancer cases
and 152 age-matched controls were included in stage 1 of the scan.
Prostate Cancer Case-Control Studies at MD Anderson
(MDA). Participants in this study were identified from
epidemiological prostate cancer studies conducted at the
University of Texas M.D. Anderson Cancer Center in the
Houston Metropolitan area since 1996. Cases were accrued
from six institutions in the Houston Medical Center and were not
restricted with respect to Gleason score, stage or PSA. Controls
were identified via random-digit-dialing or among hospital visitors
and they were frequency matched to cases on age and race.
Lifestyle, demographic, and family history data were collected
using a standardized questionnaire. These studies contributed 543
African American cases and 474 controls to this study [36].
Identifying Prostate Cancer Genes (IPCG). Cases in this
study were patients 1) undergoing treatment for prostate cancer in
the Department of Urology at Johns Hopkins Hospital from 1999
to 2007; 2) undergoing treatment at the Sidney Kimmel
Comprehensive Cancer Center from 2003 to 2007; and 3)
outside referrals as part of the Hereditary Prostate Cancer Study
from 1990 to present. Blood was obtained from groups 2) and 3)
while DNA from normal tissue was obtained from group 1). Data
are available on age at diagnosis, race, pretreatment prostate-
specific antigen (PSA) values, clinical pathology values, and family
history. The control subjects were men undergoing disease
screening and were not thought to have prostate cancer on the
basis of a physical exam and a serum PSA value below 4 ng/ml.
Screenings were performed at the Johns Hopkins Applied Physics
Lab, at Bethlehem Steel in Baltimore, and at local African
American churches in East Baltimore [7]. A total of 368 African
American cases and 172 controls contributed to stage 1.
The Los Angeles Study of Aggressive Prostate Cancer
(LAAPC). The LAAPC is a population-based case-control study
of aggressive prostate among African Americans in Los Angeles
County [37]. Cases were identified through the Los Angeles
County Cancer Surveillance Program rapid case ascertainment
system and eligible cases included African American men
diagnosed with a first primary prostate cancer between January
1, 1999 and December 31, 2003. Eligible cases also had either
tumor extension outside the prostate, metastatic prostate cancer in
sites other than prostate, or needle biopsy of the prostate with
Gleason grade 8 or higher, or Gleason grade 7 and tumor in more
than 2/3 of the biopsy cores. Controls were identified by a
neighborhood walk algorithm and were men never diagnosed with
prostate cancer, and were frequency matched to cases on age (65
years). For this study, genomic DNA was included for 296 cases
and 140 controls. We also included an additional 163 African
American controls from the MEC that were frequency matched to
cases on age.
Prostate Cancer Genetics Study (CaP Genes). The
African American component of this study population comprised
160 men: 75 cases diagnosed with more aggressive prostate cancer
and 85 age-matched controls [38]. All subjects were recruited and
frequency-matched on the major medical institutions in
Cleveland, Ohio (i.e., the Cleveland Clinic, University Hospitals
of Cleveland, and their affiliates) between 2001 and 2004. The
cases were newly diagnosed with histologically confirmed disease:
Gleason score 7; tumor stage T2c; or a prostate-specific antigen
level .10 ng/ml at diagnosis. Controls were men without a
prostate cancer diagnosis who underwent standard annual medical
examinations at the collaborating medical institutions.
Case-Control Study of Prostate Cancer among African
Americans in Washington, DC (DCPC). Unrelated men self-
described as African American were recruited for several case-
control studies on genetic risk factors for prostate cancer between
the years 2001 and 2005 from the Division of Urology at Howard
University Hospital (HUH) in Washington, DC. Control subjects
unrelated to the cases and matched for age (65 years) were also
ascertained from the prostate cancer screening population of the
Division of Urology at HUH [24]. These studies included 292
cases and 359 controls.
King County (Washington) Prostate Cancer Studies
(KCPCS). The study population consists of participants from
one of two population-based case-control studies among residents
of King County, Washington [39,40]. Incident Caucasian and
African American cases with histologically confirmed prostate
cancer were ascertained from the Seattle-Puget Sound SEER
cancer registry during two time periods, 1993–1996 and 2002–
2005. Age-matched (5-year age groups) controls were men without
a self-reported history of being diagnosed with prostate cancer and
were identified using one-step random digit telephone dialing.
Controls were ascertained during the same time periods as the
cases. A total of 145 incident African American cases and 81
African American controls were included from these studies.
The Gene-Environment Interaction in Prostate Cancer
Study (GECAP). The Henry Ford Health System (HFHS)
recruited cases diagnosed with adenocarcinoma of the prostate of
Caucasian or African American race, less than 75 years of age, and
living in the metropolitan Detroit tri-county area [41]. Controls
were randomly selected from the same HFHS population base
from which cases were drawn. The control sample was frequency
matched at a ratio of 3 enrolled cases to 1 control based on race
and five-year age stratum. In total, 637 cases and 244 controls
were enrolled between January 2002 and December 2004. Of
study enrollees, DNA for 234 African Americans cases and 92
controls were included in stage 1 of the scan.
Genotyping
Genotyping of 7,123 samples from these studies (3,621 cases
and 3,502 controls) was conducted using the Illumina Infinium
1 M-Duo bead array at the University of Southern California and
the NCI Genotyping Core Facility (PLCO study). Following
genotyping samples were removed based on the following
exclusion criteria: 1) unknown replicates across studies (n = 24,
none within studies); 2) call rates ,95% (n= 126); 3) samples with
.10% mean heterozygosity on the X chromosome and/or ,10%
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mean intensity on the Y chromosome - we inferred 3 samples to be
XX and 6 to be XXY; 4) ancestry outliers (n = 108, discussed
below), and; 5) samples that were related (n = 141, discussed
below). To assess genotyping reproducibility we included 158
replicate samples; the average concordance rate was 99.99%
($99.3% for all pairs). Starting with 1,153,397 SNPs, we removed
SNPs with ,95% call rate, MAFs,1%, or .1 QC mismatch
based on sample replicates (n = 105,411). The analysis included
1,047,986 SNPs among 3,425 cases and 3,290 controls.
Statistical Analysis
Relatedness inference. We used PLINK to calculate the
probabilities of sharing 0, 1, and 2 alleles (Z=Z0, Z1, Z2) across
all possible pairs of samples to determine individuals who were
likely to be related to others within and across studies. We
identified 167 pairs of related subjects (MZ twin, parent-offspring
pairs, full and half-sibling pairs), based on the values of their
observed probability vector Z being within 1 SD of the expected
values of Z for their respective relationship. The criterion for
removal was such that individuals that were connected with a
higher number of pairs were chosen for removal. In all other cases,
one of the two members was randomly selected for removal. A
total of 141 subjects were removed.
Global ancestry estimation. The EIGENSTRAT software
was used to calculate eigenvectors that explained genetic
differences in ancestry among samples in the study [42]. The
program included data from both HapMap Phase 3 populations
and our study, so that comparisons to reference populations of
known ethnicity could be made. An individual was subject to
filtering from the analysis if his value along eigenvector 1 or 2 was
outside of 4 SDs of the mean of each respective eigenvector. We
identified 108 individuals who met this criterion. Eigenvector 1
was highly correlated (r=0.997, p,1610216) with percentage of
European ancestry, estimated in HAPMIX [43]. Together the top
10 eigenvectors (used in the analysis) explain 21% of the global
genetic variability among subjects.
Local ancestry estimation. At each locus and for each
participant, local ancestry was defined as the estimated number of
European chromosomes (continuous between 0–2) carried by the
participant, estimated via the HAPMIX program [43]. To
summarize local ancestry at each region, for each individual we
averaged across all local ancestry estimates that were within the
start and end points of the region (Table S5). We used this average
value as an additional covariate in the risk analyses.
SNP imputation. In order to generate a dataset suitable for
fine-mapping, we carried out genome-wide imputation using the
software MACH [44]. Phased haplotype data from the founders of
the CEU (CEPH) and YRI (Yoruba) HapMap Phase 2 samples
were used to infer LD patterns in order to impute ungenotyped
markers. The Rsq metric, defined as the observed variance divided
by the expected variance, provides a measure of the quality of the
imputation at any SNP, and was used as a threshold in determining
which SNPs to filter from analysis (Rsq,0.3). Of the 1,539,328
common SNPs (MAF$0.05) in the YRI population in HapMap
Phase 2, we could impute 1,392,294 (90%) with Rsq$0.8. For all
imputed SNPs presented in the Results and Tables reported herein,
the average Rsq was 0.92 (estimated in MACH).
Association testing. For each typed and imputed SNP, odds
ratios (OR) and 95% confidence intervals (95% CI) were estimated
using unconditional logistic regression adjusting for age at
diagnosis (or age at the reference date for controls), study, the
first 10 eigenvalues and local ancestry. For each SNP, we tested for
allele dosage effects through a 1 d.f. Wald chi-square trend test.
We fine-mapped each risk locus in search of 1) a better marker
of the index signal in African Americans, and; 2) a novel signal
that is independent of the index signal. These analyses included
SNPs (genotyped and imputed) spanning 250 kb upstream and
250 kb downstream of each index signal. If the index signal was
contained within an LD block (based on the D9 statistic) of
.250 kb, then the region was extended to include the entire
region of LD. Stepwise regression was performed by region to
select the most informative risk variants as discussed below, in
models adjusted for age, study, global ancestry (the 1st eigenvector)
and local ancestry. In the stepwise regression we preserved the
original sample size by using the mean genotype of typed subjects
in place of ‘‘no-calls’’ for SNPs with ,100% genotyping
completion rate.
Within each known risk locus, it is expected that markers that
are associated with risk in African Americans will be correlated
with the index signal reported in Europeans. Thus, we identified
and tested SNPs that are correlated (r2.0.2) with the index signals
in Europeans in HapMap (CEU population). Because these
variants are not independent and there is a high prior probability
that signals exist among such variants, we applied a lenient criteria
for keeping them in the stepwise regression. The average number
of tags to capture (r2.0.8) these SNPs in each region was used as a
correction factor, as they define the number of independent tests
(p,0.004). For all of the remaining markers that were not
correlated with the index signal (in Europeans), we applied a more
stringent a level for defining statistical significance. In each risk
region, we determined the number of tag SNPs needed to capture
all common alleles (MAF.0.05, with r2.0.8) in the YRI
population in Phase 2 HapMap using single and multi-marker
tests. An a of 0.05/the total number of tags was applied to assess
statistical significance for any putative novel, independent signal in
each region (p,5.661026). For the correlated SNPs we had 80%
power to detect an OR of 1.17 per copy for a 20% risk allele,
whereas for the novel SNPs the detectable OR for such an allele
increased to 1.26 per copy. A similar stepwise analysis was also
performed at 8q24 (127.8–129.0 Mb) for SNPs with nominal p-
values,0.05, keeping SNPs if p,0.001 in the multivariate model.
This choice of p-value reflects a balance between the need to
correct for multiple comparisons and the prior knowledge that this
region harbors multiple independent risk alleles for prostate
cancer. For SNPs in the 8q24 region we had 80% power to detect
an OR of 1.19 per copy for a 20% risk allele. We tested
heterogeneity of effect by study for all 76 SNPs presented in
Table 1 and Table 2 and we observed 5 significant associations
(p,0.05, 3.6 expected) and only 1 at p,0.01 (rs7000448 at 8q24,
p = 0.004).
Risk modeling. We modeled the cumulative genetic risk of
prostate cancer using the risk variants reported in previous GWAS
(total = 40). For regions outside of 8q24 with multiple correlated
variants, we selected the SNP with the largest OR in African
Americans. At 8q24 we used the seven variants reported in Al
Olama et al. [1]. We compared the results to a model of the SNPs
found to be significantly associated with risk in African Americans,
which included the index signals if nominally associated with risk
in African Americans (p#0.05) as well as SNPs identified from the
stepwise procedures at all loci including 8q24 (total = 27). More
specifically, in each case we summed the number of risk alleles for
each individual and estimated the odds ratio per allele for this
aggregate unweighted allele count variable as an approximate risk
score appropriate for unlinked variants with independent effects of
approximately the same magnitude for each allele. For individuals
missing genotypes for a given SNP, we assigned the average
number of risk alleles (26 risk allele frequency) to replace the
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missing value for that SNP. To address the independence
assumption, we compared the betas for each SNP with the betas
obtained when all SNPs were included in the same model. We
found remarkable consistency in the betas, which supports their
associations as being independent (Table S9). We also stratified the
risk score analysis by first-degree family history of prostate cancer.
We tested for differences in the effect of the risk score by disease
severity (advanced disease defined as Gleason 8–10 and/or non-
localized stage vs non-advanced disease defined as Gleason#7 and
localized stage).
Heritability explained by the score. We estimated crudely
how much of the familial risk of prostate cancer is explained by the
known risk alleles as summarized in the improved risk score. In
this study, a first-degree family history of prostate cancer is
associated with a relative risk of 1.55 (95% CI, 1.32–1.81). Making
the simplifying assumption that all risk alleles are inherited
independently then the correlation between the risk allele count
for two first-degree relatives will be equal to 0.5 (i.e. will equal 1/2
the probability of sharing one allele IBD+the probability of sharing
two alleles IBD). Making the further assumption that the number
of risk alleles is distributed as approximately normal with
mean= 30.66 and standard deviation 3.07 alleles in the
population (estimated among African American controls) and
that in cases the mean is 32.13 alleles with roughly the same
standard deviation (3.08), we can approximate the mean number
of alleles in individuals of unknown prostate cancer status, but
each of whom has a single first-degree relative (brother or father)
with the disease as 30.66(1–0.52)+32.13(0.52) = 31.03. Since this is
just 0.37 more alleles than is expected in the control population
overall we see that the relative odds of prostate cancer for a man
with a brother or father with prostate cancer is only
exp(log(1.17)*0.37) = 1.06 higher than an unselected subject (i.e.
one not selected on the basis of disease in a first-degree relative).
Compared to the approximately 1.55-fold increase in relative risk,
this risk score may only explain ,11% [(1.0621)/
(1.5521)6100%] of risk in first-degree relatives of cases, which
indicates that many more alleles are required to explain familial
aggregation in the African American population.
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